Trial Profile
DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cisplatin
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms DART-HPV
- 19 May 2022 Planned primary completion date changed from 15 Sep 2024 to 20 Aug 2022.
- 20 Aug 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Sep 2018 Planned End Date changed from 1 Sep 2024 to 15 Sep 2024.